“In Silico Characterization of a Novel Bioactive Compound derived from Psidium guajava 4-[5-(Pyridin-4-yl)-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-amine: A Potential Inhibitor for Targeting Signaling Proteins involved in Diabetes Development”, Int. J. Pharm. Sci. Drug Res., vol. 16, no. 2, pp. 180–190, Mar. 2024, doi: 10.25004/IJPSDR.2024.160207.